Theranexus
Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies

Paris, July 15, 2015 – Created by Franck Mouthon, CEO, and Mathieu Charvériat, CSO, the biotechnology company Theranexus has announced positive results in phase 1 of its first program in the treatment of narcolepsy referred to as THN102, as well as the launch of efficacy studies.

Theranexus, a CEA spin-off, designs and develops drug combinations to improve the efficacy and safety of certain neurological and psychiatric treatments.

Bolstered by the €3.6 million raised for the THN102 program, Theranexus aims to treat narcolepsy, a disabling orphan disease chronically affecting sleep-wake cycles.
This program is based on the combination of a reference psychostimulant and a small molecule repositioned at a low dose as modulator of specific connexins in the central nervous system.

Positive results in phase 1 safety study

The crossover clinical study was performed on healthy subjects.
The results successfully showed that the combination proposed by Theranexus is safe: no issues in terms of pharmacokinetics, tolerability or cardiovascular safety were identified compared with the reference treatment (Modafinil).

Encouraged by these positive results, Theranexus plans to launch the first efficacy study in Q4 2015

The goal of this study, which will be conducted in conjunction with the French Armed Forces Biomedical Research Institute (IRBA), is to prove the efficacy of THN102 treatment on healthy subjects deprived of sleep.
This study will continue in 2016 on narcoleptic patients.

"We are delighted with the successful phase I results. They prove that our solution is safe and that it will allow us to propose this product as a response to unmet medical needs in the treatment of narcolepsy. We are more motivated than ever to pursue our program and we are actively preparing the launch of the efficacy study," said Mathieu Charvériat, CSO of Theranexus.

For his part, Franck Mouthon, CEO, thanks his financial and technical partners, especially the DGA (general Directorate for Armament), who helped to guarantee the solid and rapid implementation of this first phase and to confidently move on to the next phase.
"The phase I results are a major milestone. They safeguard the program and confirm the development choices of Theranexus. After the efficacy studies, this stage will allow us to find pharmaceutical partners to pursue the development of THN102 treatment in indications of narcolepsy but also in sleep-wake disorders," concluded Franck Mouthon.

What are narcolepsy and sleep-wake disorders?

Narcolepsy is a rare disease. It is characterized by excessive daytime sleepiness: the individual feels extreme fatigue and can uncontrollably fall asleep at an unsuitable time, at work, at school, in the street, etc.

The disease generally begins during adolescence and affects both sexes, but it can also appear later (around the age of 35). In France, an estimated 10,000 people are affected and over 500,000 are affected in the rest of the world. Some 60% to 70% of patients are currently receiving treatment that has proven insufficient, hence the need to find a new treatment to remedy this truly debilitating condition.

Other sleep-wake disorders include in particular sleep apnea or obstructive sleep apnea-hypopnea syndrome (OSAHS), a nocturnal breathing disorder characterized by abnormally frequent respiratory pauses. This syndrome affects almost 4% of the population, it leads to excessive daytime sleepiness despite current treatment.

About Theranexus

Founded in 2013 by Franck Mouthon, CEO, and Mathieu Charvériat, CSO, Theranexus is a biotechnology company designing and developing drug combinations to improve the efficacy and safety of certain neurological and psychiatric treatments.

Theranexus draws from an experienced Supervisory Board to guide it in its strategic choices and from a Scientific Council of medical and industrial experts for the company's main priorities.

In October 2014, Theranexus raised its first venture capital of €3.6 million from Auriga Partners, Sofimac Partners, CEA Investissement and Rhône-Alpes Création.

www.theranexus.com

Press contacts

ComCorp
Adélaïde Manester / Bénédicte Couturier
+33 1 58 18 32 44 - +33 6 70 45 74 37 / +33 1 84 17 84 09 - +33 6 33 58 57 24
amanester@comcorp.fr / bcouturier@comcorp.fr